Home / Search / The Pharmagellan Guide to Biotech Forecasting and Valuation
Cover of The Pharmagellan Guide to Biotech Forecasting and Valuation
ISBN-13 · 9780998407500ISBN-10 · 099840750XPublisher · Pharmagellan, LLCFormat · Paperback, 138 pagesPublished · 2017Language · English

The Pharmagellan Guide to Biotech Forecasting and Valuation

Rent this book

Free return shipping included
Total rental price$36.45

Please Note: Rental books are typically used and do not come with any unused access code cards.

Return by 2026-10-26. Prepaid return label included; extend at any point for the difference in price.

Buy from a seller

Bookface-OutletShips from CA
GoodTypical used book with minor wear and signs of use. May have some highlighting or writing.
71.74

About this book

If you're a biotech executive, investor, deal maker, entrepreneur, or adviser--or aspire to be one--then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs.

THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies.


- Vetted benchmarks for key drivers of income, expenses, and valuation.
- Proprietary analyses by Pharmagellan's experienced consulting team.
- More than 150 current references from peer-reviewed research, industry white papers, and SEC filings.

Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.

The Pharmagellan Guide to Biotech Forecasting and Valuation by Frank S David, Seth Robey, Andrew Matthews — Bookface